Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Settles $345m EpiPen Consumers Suit, But Viatris Marches On

Suit Against Viatris’ Mylan Was Set For 7 September

Executive Summary

After “four years of vigorous litigation,” Pfizer has reached a preliminary settlement over allegations that it devised an “illegal scheme” with Viatris’ Mylan “to monopolize the market” for the EpiPen autoinjector device.

You may also be interested in...



Mylan Communications With CMS To Get Outside Review Under EpiPen Settlement

Corporate integrity agreement requires Mylan to have an independent body review its drug classifications and US best price determinations; settlement resolves claims Mylan misclassified EpiPen to underpay rebates. Sanofi acted as whistleblower in case.

Alvotech Eyes $450m Funding And Public Listing With SPAC Merger

Eight years after its inception, pure-play biosimilars company Alvotech has announced plans to list on the NASDAQ via a SPAC merger that will deliver hundreds of millions in cash to fund product development and future growth.

Teva Leapfrogs Taro With Authorized Generic Epiduo Forte Launch

Teva has added another major dermatology brand to its armory, with the launch of an authorized generic version of Galderma’s Epiduo Forte Gel.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel